Rivaroxaban for post-discharge thromboprophylaxis: the MARINER trial

Int Angiol. 2018 Dec;37(6):427-430. doi: 10.23736/S0392-9590.18.04069-5.
No abstract available

Publication types

  • Editorial

MeSH terms

  • Drug Administration Schedule
  • Factor Xa Inhibitors / administration & dosage*
  • Factor Xa Inhibitors / adverse effects
  • Hemorrhage / etiology
  • Humans
  • Patient Discharge*
  • Randomized Controlled Trials as Topic
  • Rivaroxaban / administration & dosage*
  • Rivaroxaban / adverse effects
  • Venous Thromboembolism / prevention & control*

Substances

  • Factor Xa Inhibitors
  • Rivaroxaban